Empa - the place where innovation starts
Empa is the research institute for materials science and technology of the ETH Domain and conducts cutting-edge research for the benefit of industry and the well-being of society.
The Nanointercell-Group of the Particles-Biology Interactions Lab is a highly motivated team of biologists and chemists with core competences in cell- and molecular biology, material science and chemistry. We possess many years of experience and expertise in nanomaterial–biology interactions, including particle uptake, accumulation, translocation across biological barriers and their bio-responses. To enforce our team we are looking for a
Biomedical PhD Student (100%)
The main objective of the project is to establish a vascularized glioblastoma-on-a-chip model to assist in the prediction of the patient response to treatment, to screen for anti-cancer therapeutics, and to evaluate novel drug-delivery systems. In this way, we generate a relevant alternative to complement animal models being used for drug development.
We are looking for a candidate with:
- A Master's degree in cell biology, immunology, biomedical or tissue engineering or related fields within natural sciences
- A strong academic record with high university grades
- Practical experience of work on research projects
- Strong communication skills with a good command of the English language
The project includes experimental work with organoids, immune cells, fresh tissue samples from the hospital, in vitro vasculatures, use of microfluidic chips and immunohistochemistry. Experience in one of these areas, as well as a strong interest to develop a skill set in all directions is considered as a plus.
We offer an international, highly stimulating research environment with excellent infrastructure and broad interdisciplinary surroundings with plenty of possibilities for personal and professional development. You will work on an important and promising project in an international and interdisciplinary environment. The starting date is January 2023 or upon mutual agreement.